170 related articles for article (PubMed ID: 28121667)
1. Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
Jose S; Nelson M; Phillips A; Chadwick D; Trevelion R; Jones R; Williams DI; Hamzah L; Sabin CA; Post FA;
AIDS; 2017 Feb; 31(4):485-492. PubMed ID: 28121667
[TBL] [Abstract][Full Text] [Related]
2. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Gianotti N; Galli L; Poli A; Salpietro S; Nozza S; Carbone A; Merli M; Ripa M; Lazzarin A; Castagna A
Medicine (Baltimore); 2016 May; 95(22):e3780. PubMed ID: 27258510
[TBL] [Abstract][Full Text] [Related]
3. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
4. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Young J; Schäfer J; Fux CA; Furrer H; Bernasconi E; Vernazza P; Calmy A; Cavassini M; Weber R; Battegay M; Bucher HC;
AIDS; 2012 Mar; 26(5):567-75. PubMed ID: 22398568
[TBL] [Abstract][Full Text] [Related]
5. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
Nishijima T; Gatanaga H; Shimbo T; Komatsu H; Endo T; Horiba M; Koga M; Naito T; Itoda I; Tei M; Fujii T; Takada K; Yamamoto M; Miyakawa T; Tanabe Y; Mitsuya H; Oka S;
PLoS One; 2013; 8(8):e73639. PubMed ID: 23951362
[TBL] [Abstract][Full Text] [Related]
6. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Calza L; Trapani F; Salvadori C; Magistrelli E; Manfredi R; Colangeli V; Di Bari MA; Borderi M; Viale P
Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
[TBL] [Abstract][Full Text] [Related]
7. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
Harris M; Ganase B; Watson B; Hull MW; Guillemi SA; Zhang W; Saeedi R; Harrigan PR
HIV Clin Trials; 2017 Jan; 18(1):39-47. PubMed ID: 28067119
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
Tanaka H; Arai M; Tomoda Y; Wada T; Yago K; Satoh M
J Pharm Pharm Sci; 2013; 16(3):405-13. PubMed ID: 24021289
[TBL] [Abstract][Full Text] [Related]
10. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.
Perry ME; Taylor GP; Sabin CA; Conway K; Flanagan S; Dwyer E; Stevenson J; Mulka L; McKendry A; Williams E; Barbour A; Dermont S; Roedling S; Shah R; Anderson J; Rodgers M; Wood C; Sarner L; Hay P; Hawkins D; deRuiter A
HIV Med; 2016 Jan; 17(1):28-35. PubMed ID: 26200570
[TBL] [Abstract][Full Text] [Related]
12. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
Bánhegyi D; Katlama C; da Cunha CA; Schneider S; Rachlis A; Workman C; De Meyer S; Vandevoorde A; Van De Casteele T; Tomaka F
Curr HIV Res; 2012 Mar; 10(2):171-81. PubMed ID: 22339125
[TBL] [Abstract][Full Text] [Related]
13. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
14. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
Costagliola D; Potard V; Lang S; de Castro N; Cotte L; Duval X; Duvivier C; Grabar S; Mary-Krause M; Partisani M; Ronot-Bregigeon S; Simon A; Tattevin P; Weiss L; Zucman D; Katlama C; Raffi F; Boccara F
J Infect Dis; 2020 Feb; 221(4):516-522. PubMed ID: 31828320
[TBL] [Abstract][Full Text] [Related]
15. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
[TBL] [Abstract][Full Text] [Related]
17. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Mocroft A; Lundgren JD; Ross M; Fux CA; Reiss P; Moranne O; Morlat P; Monforte Ad; Kirk O; Ryom L;
Lancet HIV; 2016 Jan; 3(1):e23-32. PubMed ID: 26762990
[TBL] [Abstract][Full Text] [Related]
18. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.
Stanley TL; Joy T; Hadigan CM; Liebau JG; Makimura H; Chen CY; Thomas BJ; Weise SB; Robbins GK; Grinspoon SK
AIDS; 2009 Jul; 23(11):1349-57. PubMed ID: 19474651
[TBL] [Abstract][Full Text] [Related]
19. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]